The Effect of Dorzolamide Ophthalmic Drops in the Treatment of Patients with Central Serous Chorioretinopathy

Abstract

Background and Objective: Central Serous Chorioretinopathy (CSCR) is a common retinal disorder. The aim of this study was to evaluate the effectiveness of 2% dorzolamide eye drops in accelerating the recovery from acute CSCR. Methods: This single-blind non-randomized clinical trial included a total of 45 patients with acute CSCR. The case group (26 people who received 2% Dorsolamide eye drops twice a day for three weeks) and the control group (19 people) were studied. CSCR improvement rates were evaluated and compared by fundoscopic examination and Optical Coherence Tomography (OCT) images before and three weeks after the intervention. Findings: The two groups were homogeneous in terms of age, sex, and baseline visual acuity. Patients in Dorzolamide group showed a significant reduction in central macular thickness as measured by OCT for both the right (-180.36±152.74 µm, p<0.001) and left (-161.87±144.08 µm, p=0.004) eyes compared to control group. Moreover, 84.6% of patients in Dorzolamide group and 21% in the control group recovered from CSCR. CSCR recurred in two male patients in the control group, while no relapse was observed in Dorzolamide group within one month following treatment. Conclusion: Our findings suggest that the use of 2% Dorzolamide eye drops twice daily for three weeks significantly reduces central macular thickness, disease duration, one-month recurrence, and the need for laser treatment in patients with CSCR.

Keywords

• central serous chorioretinopathy
• dorzolamide
• optical coherence tomography.